POST MI/HFrEF

Study Name: BioCardia

Study Objective: To evaluate safety/efficacy of CardiAMP cell therapy system in patients with post MI HF.

Key Inclusion Criteria:

• Previous MI (> 6 months)  
• EF ≥ 20% and ≤ 40% by echo
• On stable evidence-based medical and device therapy for HF or post-infarction left ventricular dysfunction